title: The effect of hydrochloride pioglitazone on urinary 8-hydroxy -deoxyguanosine excretion in type 2 diabetics.
abstract: OBJECTIVE
  To observe the effects of hydrochloride pioglitazone on urinary 8-hydroxy-deoxyguanosine (8OHdG) excretion in type 2 diabetics and explore its possible reno-protective mechanisms.
  
  
  METHODS
  Ninety-eight uncontrolled type 2 diabetics were assigned randomly into group DP (pioglitazone add-on) and group DS (sulfonylureas add-on). At the basal and after 12 weeks treatment, FBG, HbA1c, urinary 8-OHdG, urinary albumin(ALB) and urinary creatinine (Cr) were determined, respectively.
  
  
  RESULTS
  Compared with pre-treatment, FBG, HbA1c and urinary 8-OHdG /Cr ratio(U8CR) were all obviously decreased in both therapy groups; urinary albumin/urinary creatinine ratio(UACR) markedly decreased in group DP (P<0.01), while slightly decreased in group DS (P>0.05) after twelve weeks of observation. After 12-week treatment, UACR and U8CR in group DP were significantly lower than those in group DS (both P<0.05) without no marked difference in FBG and HbA1c between group DP and group DS. Meanwhile, U8CR had positive correlation with UACR (r=0.755, P<0.01).
  
  
  CONCLUSIONS
  Pioglitazone can decrease urinary 8-OHdG excretion and lighten oxidative stress in vivo in type 2 diabetics, which may play a protective role for the kidney damage.
authors.affiliation: Department of Endocrinology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei 230001, PR China.
authors.forename: Yuefen
authors.initials: Y
authors.lastname: Wang
authors.forename: Shandong
authors.initials: S
authors.lastname: Ye
authors.forename: Yuanyuan
authors.initials: Y
authors.lastname: Hu
authors.forename: Lili
authors.initials: L
authors.lastname: Zhao
authors.forename: Mao
authors.initials: M
authors.lastname: Zheng
mesh_terms: D000080242:8-Hydroxy-2'-Deoxyguanosine; D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D003849:Deoxyguanosine / Q000031:analogs & derivatives* / Q000652:urine; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000652:urine*; D005260:Female; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D008297:Male; D008657:Metabolic Clearance Rate / Q000187:drug effects; D008875:Middle Aged; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000008:administration & dosage*
chemical_list: D000080242:8-Hydroxy-2'-Deoxyguanosine; D001786:Blood Glucose; D003849:Deoxyguanosine; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000077205:Pioglitazone; D045162:Thiazolidinediones; C517652:hemoglobin A1c protein, human